Who owns Vaxcyte, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PCVX from SEC Form 13F filings across 331 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 331 institutions disclosed 167.0M shares of Vaxcyte, Inc. worth $9.71B — about 115.6% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
331
13F holders
$9.71B
value, 2026 filers
115.6%
of shares outstanding (167.0M sh)
50
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of PCVX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 20.9M | $1.21B | 0.1% | 14.4% | +26.4% |
| 2 | Jupiter Topco LLCNEW | 18.0M | $1.04B | 0.4% | 12.4% | new |
| 3 | T. Rowe Price Investment Management, Inc. | 12.2M | $709.6M | 0.5% | 8.4% | +0.7% |
| 4 | BlackRock, Inc. | 12.1M | $701.5M | 0.0% | 8.4% | +10.0% |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 11.5M | $667.0M | 5.8% | 7.9% | 0.0% |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 7.0M | $407.0M | 0.1% | 4.8% | +24.7% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M | $383.3M | 0.0% | 4.6% | +5.0% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | $369.0M | 0.0% | 4.4% | +1.3% |
| 9 | STATE STREET CORP | 5.4M | $311.1M | 0.0% | 3.7% | +20.5% |
| 10 | Deep Track Capital, LP | 4.3M | $250.0M | 3.6% | 3% | 0.0% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $201.1M | 0.0% | 2.4% | +8.1% |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.0M | $173.8M | 0.0% | 2.1% | +206.1% |
| 13 | Kynam Capital Management, LP | 2.9M | $169.9M | 9.4% | 2% | 0.0% |
| 14 | WESTFIELD CAPITAL MANAGEMENT CO LP | 2.5M | $143.7M | 0.5% | 1.7% | -32.2% |
| 15 | Caligan Partners LP | 2.2M | $127.2M | 6.0% | 1.5% | +6.2% |
| 16 | Paradigm Biocapital Advisors LP | 2.1M | $123.7M | 2.3% | 1.5% | -55.6% |
| 17 | Bellevue Group AG | 2.0M | $114.6M | 2.4% | 1.4% | +65.6% |
| 18 | D. E. Shaw & Co., Inc. | 1.9M | $110.6M | 0.1% | 1.3% | -33.6% |
| 19 | MAVERICK CAPITAL LTD | 1.6M | $93.8M | 0.8% | 1.1% | +17.1% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.5M | $85.1M | 0.0% | 1% | +4.3% |
| 21 | Pivotal bioVenture Partners Investment Advisor LLC | 1.4M | $82.9M | 26.9% | 1% | +3.9% |
| 22 | EVENTIDE ASSET MANAGEMENT, LLC | 1.4M | $80.2M | 1.1% | 1% | +0.4% |
| 23 | GOLDMAN SACHS GROUP INC | 1.4M | $78.5M | 0.0% | 0.9% | +5.9% |
| 24 | NORTHERN TRUST CORP | 1.3M | $74.4M | 0.0% | 0.9% | +11.9% |
| 25 | NORGES BANKNEW | 1.2M | $72.4M | 0.0% | 0.9% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.